Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry.
Beyer-Westendorf J, Gelbricht V, Förster K, Ebertz F, Röllig D, Schreier T, Tittl L, Thieme C, Hänsel U, Köhler C, Werth S, Kuhlisch E, Stange T, Röder I, Weiss N.
Beyer-Westendorf J, et al. Among authors: kuhlisch e.
Br J Clin Pharmacol. 2014 Oct;78(4):908-17. doi: 10.1111/bcp.12391.
Br J Clin Pharmacol. 2014.
PMID: 24697922
Free PMC article.